7.8
One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the princip…
The first-order absorption model for extravascular administration considers the rate at which a drug is absorbed, distributed in body tissues, and eliminated to follow first-order kinetics.
This model provides a mathematical representation of drug absorption and elimination. It helps predict and interpret drug behavior within the body.
Here, the rate of change in drug concentration over time can be expressed using mathematical equations.
Vital pharmacokinetic parameters can be calculated, including peak plasma concentration and the time taken to reach it.
The absorption rate constant can be determined using the method of residuals or Wagner-Nelson method.
This model can be illustrated as a plasma drug concentration-time profile consisting of absorption and elimination phases.
The plasma drug concentration-time curve may exhibit the flip-flop phenomenon, where the meanings of the slopes representing absorption and elimination interchange.
The lag time signifies the delay between drug administration and the initiation of absorption.
View the full transcript and gain access to JoVE Core videos
Q1: What does the first-order absorption model describe in pharmacokinetics?
The first-order absorption model for extravascular administration describes how a drug is absorbed and eliminated following first-order kinetics principles. It provides a mathematical representation of drug behavior within the body, allowing prediction and interpretation of drug absorption and elimination based on changes in drug concentration over time.
Q2: How are peak plasma concentration and time to peak concentration determined?
Peak plasma concentration (Cmax) and the time required to reach it (tmax) are crucial pharmacokinetic parameters calculated using the first-order absorption model. These values are derived from the plasma concentration-time profile and help clinicians understand drug efficacy and optimal dosing intervals.
Q3: What methods are used to determine the absorption rate constant?
The absorption rate constant can be determined using the method of residuals or the Wagner-Nelson method. These analytical approaches extract absorption kinetics from plasma concentration-time data, enabling accurate characterization of how quickly a drug enters systemic circulation after extravascular administration.
Q4: What is lag time in drug absorption?
Lag time (t0) represents the delay between drug administration and the initiation of absorption. If the extrapolated and residual lines intersect at the y-axis at time t = 0, there is no lag. However, if intersection occurs at a time greater than zero, this indicates a time lag in the absorption process.
Q5: What is the flip-flop phenomenon in plasma concentration-time curves?
The flip-flop phenomenon refers to an interchange in the meanings of slopes representing absorption and elimination in the plasma concentration-time curve. During this phenomenon, a longer duration of drug sampling may be necessary to avoid overestimating the fraction of drug absorbed and to accurately characterize pharmacokinetic parameters.
Q6: How does the plasma concentration-time profile illustrate drug behavior?
The plasma concentration-time profile visualizes the first-order absorption model as a curve comprising absorption, post-absorption, and elimination phases. This graphical representation helps clinicians and researchers interpret drug kinetics, identify absorption and elimination rates, and predict drug concentrations at different time points.
Q7: Why is the first-order absorption model important for drug therapy?
The first-order absorption model is vital because it provides mathematical representation enabling prediction and interpretation of drug behavior within the body. By calculating vital pharmacokinetic parameters and understanding absorption and elimination rates, clinicians can optimize dosing regimens and ensure therapeutic efficacy.